esubio

Pharmacopoeia Compliance: 5 Costly Gaps Hiding in Your COA Your COA says compliant. But compliant to which pharmacopoeia, for which target market, and did the test method actually match your finished product’s registration requirements? In nutraceutical ingredient procurement, pharmacopoeia compliance has quietly become the gap that surfaces at the worst possible moment — during a

Nutraceutical Ingredient Sourcing From China: The Hidden Cost Guide Nutraceutical ingredient sourcing from China now accounts for more than 60 percent of global output, and for procurement managers and R&D directors at OEM and ODM factories, that shift changes the math on almost every raw material line item. If your current COA reads 99 percent

Curcuminoid COA Analysis: 5 Questions to Ask Before You Approve a Batch Every week, procurement teams and formulators approve ingredient purchases based on a single number printed on a Certificate of Analysis — “95% curcuminoids by HPLC.” It looks authoritative. It looks scientific. It can also be incomplete. A proper curcuminoid COA analysis goes beyond

Pharmacopoeial Grade Ingredient Supplier: 6 Critical Testing Gaps to Avoid Most procurement conversations stop at the Certificate of Analysis. Fewer stop at the question that actually matters: which pharmacopoeial standard was that CoA tested against — and does it match your finished product’s target market? USP, Ph. Eur., and BP are not interchangeable labels. They

Curcumin COA Checklist: 7 Questions to Ask Before You Buy A curcumin COA checklist is the fastest way to catch an inflated purity claim before it costs you a shipment. If your supplier just sent over a COA showing “Curcumin 95%,” this checklist tells you exactly which numbers on that page are the ones suppliers

China Ingredient Supplier: 7 Critical Reasons You’re Overpaying in 2026 If your OEM factory or brand is still sourcing functional ingredients exclusively from Western suppliers, you may be paying significantly more than necessary. Working with a China ingredient supplier is no longer just a cost play — it reflects a structural shift in how the